SCHEDULE: Vanguard Group Reports Zero Stake in Viridian Therapeutics

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Viridian Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Viridian Therapeutics Inc. common stock.
• As of the filing date, The Vanguard Group reports 0% beneficial ownership of Viridian Therapeutics Inc. common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. It reflects an internal corporate restructuring for reporting purposes rather than a change in investment strategy or a direct divestment decision related to Viridian Therapeutics Inc.

Positives

• The filing provides clarity on The Vanguard Group's current reporting structure, indicating a streamlined approach for its various investment entities.

Negatives

• The Vanguard Group, as the parent entity, no longer directly reports beneficial ownership in Viridian Therapeutics Inc., which might be perceived as a reduction in direct institutional interest from the parent organization.

Risks

• The disaggregation of beneficial ownership reporting means that the total institutional holding by all Vanguard-affiliated entities in Viridian Therapeutics Inc. is no longer consolidated under The Vanguard Group, Inc. in this specific filing, potentially requiring investors to review multiple filings to ascertain the full Vanguard-related stake.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Viridian Therapeutics Inc. or The Vanguard Group's future investment intentions beyond the structural change in reporting.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that internal realignments and subsequent changes in reporting structures, such as the disaggregation of beneficial ownership, are common among large asset managers like The Vanguard Group. This move aims to streamline compliance with SEC regulations, particularly Rule 13d-1(b), by allowing individual investment advisory subsidiaries to report their holdings independently. This practice is consistent with how other diversified financial institutions manage their various investment arms.

Comparison to Industry Standards

• This filing reflects a standard practice for large, diversified investment firms like BlackRock or State Street, where various funds and advisory units may report their holdings separately to comply with SEC regulations.
• The disaggregation of reporting aligns with the principles outlined in SEC Release No. 34-39538, which provides guidance on beneficial ownership reporting for parent holding companies and their subsidiaries, ensuring compliance with regulatory expectations for complex organizational structures.

Stakeholder Impact

• Shareholders of Viridian Therapeutics Inc. may observe a change in the reported institutional ownership by The Vanguard Group, Inc. as a single entity, although underlying holdings by Vanguard's subsidiaries may persist.
• Investors tracking Vanguard's holdings will need to monitor filings from individual Vanguard subsidiaries for a complete picture of Vanguard-affiliated beneficial ownership in Viridian Therapeutics Inc.

Next Steps

• Individual subsidiaries or business divisions of The Vanguard Group, Inc. will report their beneficial ownership of Viridian Therapeutics Inc. separately in future filings, consistent with the new internal reporting structure.

Key Dates

Recommendation

This filing is purely an administrative update regarding The Vanguard Group's internal reporting structure and beneficial ownership disclosure. It does not reflect a change in investment thesis for Viridian Therapeutics Inc. or a direct divestment decision by Vanguard. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Viridian Therapeutics Inc. The 'hold' recommendation reflects the lack of new actionable information from this specific filing.

Keywords

Vanguard Group, Viridian Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Ownership, Investment Adviser, Common Stock, SEC Filing, Ownership Change, Corporate Realignment